Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
Biomarin and Ascendis Pharma settled a patent dispute over achondroplasia drugs. Biomarin will receive 18–20% royalties on Yuviwel sales until 2030. Analysts view the agreement as favorable for both companies, with Ascendis gaining market access and Biomarin securing high royalties.
How this was made
The 30-second read
Why it matters
The settlement provides Biomarin a new revenue stream while allowing Ascendis to commercialize Yuviwel without litigation risk.
Market read
Both companies face altered financial outlooks; investors should reassess revenue forecasts and margin expectations.
What to watch
Future competition from Biomarin's BMN 333 could further pressure Yuviwel's market share.
Background
Biomarin and Ascendis resolved a patent dispute over achondroplasia therapies, establishing a royalty framework.
Ticker impact
Biomarin secured an 18‑20% royalty on Ascendis' Yuviwel sales through 2030, a new high‑teens settlement.
Biomarin may see modest upside as royalty stream materializes.
Royalty rate is higher than typical biotech settlements and provides a new cash flow source.
Ascendis agreed to pay 18‑20% royalties to Biomarin, clearing a patent dispute and allowing Yuviwel to launch unimpeded.
Short‑term pressure from royalty cost may be offset by unhindered market launch.
The settlement removes a legal cloud, supporting sales momentum despite added royalty burden.
Market effects
The deal highlights growing royalty‑based licensing in biotech rare‑disease space.
U.S. biotech sector may see modest re‑rating as settlement sets precedent.
International peers with CNP programs may face similar licensing negotiations.
Counterpoint
The royalty burden could materially dent Ascendis' profitability, outweighing launch benefits.
Key entities
- CompanyBiomarin Pharmaceutical Inc.
Developer of Voxzogo, now receiving royalties from Ascendis.
- CompanyAscendis Pharma plc
Developer of Yuviwel, agreeing to pay royalties to Biomarin.
